Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

ABT-737

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

AbbVie

Drug class:

Bcl2 antagonist

MEF2C overexpression	T Acute Lymphoblastic Leukemia	MEF2C overexpression	T Acute Lymphoblastic Leukemia	ABT-737 Sensitive: D – Preclinical ABT-737 Sensitive : D	ABT-737 Sensitive: D – Preclinical ABT-737 Sensitive : D
RET L629P	Head and Neck Cancer	RET L629P	Head and Neck Cancer	vorinostat + ABT-737 Sensitive: D – Preclinical vorinostat + ABT-737 Sensitive : D	vorinostat + ABT-737 Sensitive: D – Preclinical vorinostat + ABT-737 Sensitive : D
KRAS G12D	Non Small Cell Lung Cancer	KRAS G12D	Non Small Cell Lung Cancer	ABT-737 Sensitive: D – Preclinical ABT-737 Sensitive : D	ABT-737 Sensitive: D – Preclinical ABT-737 Sensitive : D